Ipsen Group

Ipsen is a global specialty-driven biopharmaceutical group committed to discovering new solutions for targeted debilitating diseases and improving quality of life for patients.

Ipsen Group

Ipsen is a global biopharmaceutical group dedicated to improving lives and health outcomes through innovative medicines in Oncology, Neuroscience and Rare Disease.  We also have a well-established and successful Consumer Healthcare business.  We are committed to discovering new treatments in areas with high unmet medical needs and improving the quality of life for patients.

Ipsen group

Therapeutic areas

Ipsen is a global biopharmaceutical group dedicated to improving lives and health outcomes through innovative medicines in Oncology, Neuroscience and Rare Disease.  We also have a well-established and successful Consumer Healthcare business. We are committed to developing new treatments in areas with high unmet medical needs and improving the quality of life for patients.

 

Executive management

* members of the Executive Leadership Team

David Loew*

Chief Executive Officer

Bartosz (Bartek) Bednarz*

Executive Vice President,

Head of Global Product and Portfolio Strategy

Dominique Bery*

Executive Vice President, Strategy & Transformation

François Garnier*

Executive Vice President,

General Counsel

Benoît Hennion*

Executive Vice President,

CHC

Steven Hildemann*, M.D., PhD

Executive Vice President,

Chief Medical Officer, Head of Global Medical Affairs, Patients Safety and Patients Affairs

Dominique Laymand*

Executive Vice President,

Ethics and Social Responsibility Officer

Aymeric Le Chatelier*

Executive Vice President,

Group Chief Financial Officer

Philippe Lopes-Fernandes*

Executive Vice President,

Chief Business Officer

Howard Mayer*, M.D.

Executive Vice President,

Head of Research and Development.

Régis Mulot*

Executive Vice President,

Chief Human Resources Officer

Aidan Murphy*

Executive Vice President,

Technical Operations

Gwenan White*

Executive Vice President,

Communications and Public Affairs

Patrice Zagame*

Executive Vice President,

Specialty Care International

Board Committees

The Board of Directors has set up six permanent committees and has defined both the composition and powers of these committees.

Ipsen history

Strategy

Mid-term financial outlook and capital allocation strategy

Ipsen provides its financial outlook for the period 2020-20241:

  • Group Net Sales CAGR2 between +2% and +5%3,assuming potential additional indications
  • Commitment to invest in R&D supported by SG&A efficiencies
    • Lower SG&A as a percentage of net sales driven by further focus and optimization
    • Higher R&D as a percentage of net sales driven by external innovation strategy

External innovation is Ipsen’s number one priority for capital allocation. In support of its external innovation strategy, Ipsen expects to generate by 2024 a cumulative €3bn4 of firepower for pipeline expansion, excluding the sale of any assets.

1 Ipsen is on track to deliver its previous 2022 financial targets and is committed now to a new 2024 financial outlook

2 Compound Annual Growth Rate

3 At constant exchange rates and scope

4 Based on Net Debt remaining below 2.0x EBITDA

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved. - 2021